Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-03-06

Study Completion Date

2023-01-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study was to determine the safety and test the efficacy of the combination of radium-223 dichloride and pembrolizumab in patients with stage IV non-small cell lung cancer (NSCLC) with bone metastases who either had not received any systemic therapy for their advanced disease or had progressed on prior immunologic checkpoint blockade with antibodies against the programmed cell death protein-(ligand) 1 (PD-1/PD-L1). In this study researchers wanted to measure tumor shrinkage in response to treatment and how long that shrinkage lasted and gathered information on safety. Pembrolizumab is an immunologic checkpoint blocker that promotes an immune response against the tumor. Radium-223 dichloride is an alpha particle-emitting radioactive agent which kills cancer cells.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers

NCT02303990

Metastatic Cancers

COMPLETED PHASE1

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

NCT04624204

Small Cell Lung Cancer

ACTIVE_NOT_RECRUITING PHASE3

Study of Pembrolizumab and Chemotherapy With or Without Radiation in Small Cell Lung Cancer (SCLC)

NCT02934503

Small Cell Lung Cancer (SCLC)

TERMINATED PHASE2

Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC

NCT04153734

Locally Advanced Non-small Cell Lung Cancer

NOT_YET_RECRUITING PHASE2

Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas

NCT03233724

Carcinoma, Non-Small-Cell Lung Lung Cancer Non-Small Cell Lung Cancer +2 more

TERMINATED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Carcinoma, Non-Small-Cell Lung

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Phase 1: Radium-223+Pembrolizumab

Participants received radium-223 dichloride at 55 kBq/kg every 6 weeks in combination with pembrolizumab every 3 weeks.

Group Type EXPERIMENTAL

Radium-223 dichloride (Xofigo, BAY 88-8223)

Intervention Type DRUG

55 kBq/kg, intravenous (IV) injection, every 6 weeks for up to 6 administrations

Pembrolizumab

Intervention Type DRUG

200 mg, IV infusion, every 3 weeks for a maximum of up to 35 administrations

Phase 2 Cohort 1: Radium-223+Pembrolizumab

Participants was planned to receive radium-223 dichloride at the maximum tolerated dose (MTD) to be determined in the Phase 1 part every 6 weeks in combination with 200 mg pembrolizumab every 3 weeks.

Group Type EXPERIMENTAL

Radium-223 dichloride (Xofigo, BAY 88-8223)

Intervention Type DRUG

55 kBq/kg, intravenous (IV) injection, every 6 weeks for up to 6 administrations

Pembrolizumab

Intervention Type DRUG

200 mg, IV infusion, every 3 weeks for a maximum of up to 35 administrations

Phase 2 Cohort 1: Pembrolizumab alone

Participants was planned to receive 200 mg pembrolizumab every 3 weeks.

Group Type ACTIVE_COMPARATOR

Pembrolizumab

Intervention Type DRUG

200 mg, IV infusion, every 3 weeks for a maximum of up to 35 administrations

Phase 2 Cohort 2: Radium-223+Pembrolizumab

Participants was planned to receive radium-223 dichloride at the MTD to be determined in the Phase 1 part every 6 weeks in combination with 200 mg pembrolizumab every 3 weeks.

Group Type EXPERIMENTAL

Radium-223 dichloride (Xofigo, BAY 88-8223)

Intervention Type DRUG

55 kBq/kg, intravenous (IV) injection, every 6 weeks for up to 6 administrations

Pembrolizumab

Intervention Type DRUG

200 mg, IV infusion, every 3 weeks for a maximum of up to 35 administrations

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Radium-223 dichloride (Xofigo, BAY 88-8223)

55 kBq/kg, intravenous (IV) injection, every 6 weeks for up to 6 administrations

Intervention Type DRUG

Pembrolizumab

200 mg, IV infusion, every 3 weeks for a maximum of up to 35 administrations

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically or cytologically confirmed diagnosis of stage IV NSCLC.

* Phase 2 Cohort 1: No Epidermal Growth Factor Receptor (EGFR) / v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation or anaplastic lymphoma kinase (ALK)/ROS1 rearrangement. Treatment naïve (no prior systemic therapy) for their metastatic NSCLC.
* Phase 2 Cohort 2: progression on prior treatment with an immune checkpoint inhibitor inhibitor. Prior treatment with platinum-based chemotherapy in combination or in sequence in line with local standard of care.
* Phase 1 includes participants meeting either Cohort 1 or Cohort 2 criteria.
* Measurable disease per RECIST v1.1.
* At least 2 skeletal metastases.
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0 or 1.
* Adequate bone marrow and organ function.
* Participants must be on a bone health agent (BHA) treatment, such as bisphosphonates or denosumab treatment unless such treatment is contraindicated or not recommended per investigator's judgement.

Exclusion Criteria

* Previous or concurrent cancer within 3 years prior to enrollment.
* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor. Phase 2 Cohort 2: was discontinued from that treatment due to a Grade 3 or higher immune-related AEs (irAEs).
* Known active central nervous system metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate provided they are radiologically stable, clinically stable, and without requirement of steroid treatment for at least 14 days prior to first dose of study treatment.
* Active autoimmune disease that has required systemic treatment in the past 2 years.
* History of (non-infectious) pneumonitis that required steroids or has current pneumonitis.
* Known history or presence of osteonecrosis of jaw.
* Ongoing infection \>Grade 2 NCI-CTCAE v.5.0 requiring systemic therapy.
* Significant acute GI disorders with diarrhea as a major symptom e.g., Crohn's disease, malabsorption, or ≥ NCI-CTCAE v.5.0 Grade 2 diarrhea of any etiology.
* History of osteoporotic fracture.
* Prior treatment with radium-223 dichloride or any therapeutic radiopharmaceutical.
* Prior radiotherapy within 21 days of planned start of study treatment.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No